Every year the Archives of Toxicology celebrate the most cited authors (Table 1) . As expected apoptosis, metal toxicity, oxidative stress and regulatory toxicology represented hot topics. The editors would like to highlight two outstanding articles, written by O'Brien et al. (2006) and a review by Greim et al. (2006) , because both articles demonstrate important aspects of the current debate about replacement of in vivo studies by in vitro tests. O'Brien and colleagues performed a large validation study about prediction of human hepatotoxicity by a human hepatoma cell line in vitro. Human hepatocytes and also hepatocyte cell lines are frequently used for in vitro studies of toxicity, drug metabolism and enzyme induction (Hewitt et al. 2007; Hengstler et al. 2000; Brulport et al. 2007) . Many examples of excellent correlations between in vitro data with hepatocytes and the in vivo situation have been published (Gebhardt et al. 2003; Hengstler et al. 2000; Carmo et al. 2005) . However, well-designed validation studies including sufficient numbers of substances are rare. O'Brien and colleagues used a standardized in vitro test with human HepG2 cells and analyzed a well-chosen battery of endpoints. The authors studied 243 compounds with varying degree of toxicity. Overall human toxicity potential was detected with 80% sensitivity and 90% specificity. This is an important study, and also the most cited article published in the Archives between 2006 and 2007. Considering the limitations of an in vitro system based on HepG2 cells, such as incomplete metabolic competence or toxicities mediated by other cell types than hepatocytes, the result is encouraging.
Without doubt well-validated in vitro tests, such as the human hepatocyte screening assay of O'Brien et al. can be used to identify substances with an increased potential to cause specific toxic effects, such as hepatotoxicity in the case of O'Brien's test strategy. This is indeed an important progress. However, two major limitations remain. First, an in vitro test using one particular primary cell type, such as the hepatocytes or a hepatocyte cell line, may have the potential to predict liver toxicity but not toxicity to other organs (which was of course not intended by the authors). Second, at the present state of the art in vitro studies only allow screening for specific hazardous properties but information about in vivo dose-response relationships and identification of NOELS cannot be obtained. This is where the review of Helmut Greim and further recognized European Toxicologists comes in (Greim et al. 2006) . The authors discuss one of the problematic aspects of the new European chemicals legislation REACH according to which repeated dose studies may only be required for substances produced beyond 100 t/year. This means that most of the substances will not be studied by repeated dose tests such as 28-and 90-day studies. The authors criticize that in the absence of such information the hazard identification will be incomplete. Alternative in vitro studies alone will not identify all relevant endpoints of in vivo toxicity and can not identify thresholds and NOELS. Therefore, the authors criticize that a premature replacement of in vivo tests primarily considers cost reduction and protection of animals, whereas the protection of human health and the environment are secondary. The editors feel that this is an important contribution to the recent debate. It also leads to the discussion to which extent and when we will be able to predict NOELS only by in vitro tests. The latter has recently been discussed in this journal by Lilienblum et al. (2008) task. In principle, all individual problems associated with in vitro in vivo extrapolation can be solved by pharmacokinetic modelling. However, the difficulty is complexity and the necessity to take into account all relevant factors of influence. In some future it may be possible to predict in vivo toxicity only by in vitro tests. We can not say whether this will be achieved in 15 or in 50 years. However, we can say for sure that this goal can not be achieved within 5 years. In the meantime as outlined by Greim and colleagues we have two possibilities (Greim et al. 2006) : Continue the existing methods until reliable in vitro techniques are available or reduce the quality of hazard and risk evaluation which will probably be associated with adverse consequences for human health. A polymorphism of the delta-aminolevulinic acid dehydratase gene (ALAD 1-2/2-2) identifies subjects with increased susceptibility to lead exposure
